Search 

AlzProtect  We develop innovative drugs for the treatment of Neurodegeneration Industry sectors Biotech Therapeutics Area CNS-Neurology
Your innovative solution

We develop AZP2006 a first-in-class small molecule which modulates protein homeostasis. AZP2006 revolutionary mode of action has been shown to prevent Tau hyperphosphorylation and aggregation in vivo. Its nadditional neuroprotective properties allow to prevent both cognition and motor deficiencies induced by amyloid and other neurotoxics. AZP2006 will nter clinical phase 2 in 2016. It has obtained an orphan drug status for the treatment of PSP.

Which problem are you solving ?

AZP2006 is developed for the prevention and treatment of neurodegenerative diseases such as Alzheimer's disease and Progressive Supranuclear Palsy.

Target market segments

Alzheimer's disease, Progressive supranuclear palsy, Frontotemporal dementia, Parkinson's disease

Key value proposition

Innovative mode of action/ first-in-class candidate drug/ clinical phase / Orphan status

AMA, 1 in 10 companies certified "Glass Partner" by Google worldwide, provides mobile and hands-free tele-expertise solutions on smart glasses, mainly in the medical fields. Industry sectors E_health Therapeutics Area Cardiology / Vascular Diseases
CNS-Neurology
Dermatology
Gastroenterology / Hepatology
Orthopedics/Orthopedic Surgery
Pediatrics/Neonatology
Your innovative solution

Hands-free, mobile audio-video connection on smart glasses through a HIPAA exchange platform allowing the physician to communicate with the patient and nurse, permitting synchronous tele-consultations. Doctors can take pictures remotely, select areas within the photo to highlight, comment on and transfer to the nurse and patient file.

Which problem are you solving ?

-TELEMEDICINE: AMA's solution brings healthcare expertise to patients, eliminating geographical constraints and improving quality care and patient comfort. - FINANCIAL challenges: reduces transport, hospitalisation costs and time consumption. - EMERGENCY: fast intervention, doubt removal, orientation to best-fitting hospital - E-LEARNING and mentoring: Live and personalised advice and guidance during training/interventions

Target market segments

Emergency 1 / Ambulances 2 / Nursing homes 3 / E-training 4

Key value proposition

Mobility 1 / Hands-free 2 / Videoconferencing (audio - video exchanges) 3 / Efficient (cost and time saving) 4

Contacts:

• Jean-François DENIS, VP Sales
• Anne-Fleur ANDRLE, Business Development US

AMABIOTICS Amabiotics is a biopharmaceutical company developing innovative microbiome medicines to fight neurodegenerative diseases Industry sectors BioPharma Therapeutics Area CNS-Neurology
Rare Disease
Your innovative solution

AMABIOTICS analyse metabolic interplays between humans and its microbial associated communities. AMABIOTICS discovered novel actions of natural chemical compounds provided by the microbiome that the host cannot synthesize by itself. Our pipeline of products candidates is led by AMA-101 as a potential first-in-class therapy for Parkinson disease.

Which problem are you solving ?

We address the major issue of preventing mitochondrial dysfunction

Target market segments

1 - Neurodegenerative disease / 2 - Obesity / 3 - Tissue regeneration

Key value proposition

Original and specific mode of action / Crosses the blood-brain barrier / Co-evolution with our organism (low risk of adverse side effect).

About the American Heart Association

The American Heart Association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. Founded by six cardiologists in 1924, our organization now includes more than 22.5 million volunteers and supporters. We fund innovative research, fight for stronger public health policies, and provide critical tools and information to save and improve lives. Our nationwide organization includes 156 local offices and more than 3,000 employees. We moved our national headquarters from New York to Dallas in 1975 to be more centrally located. The American Stroke Association was created as a division in 1997 to bring together the organization’s stroke-related activities.

What We Do: To improve the lives of all Americans, we provide public health education in a variety of ways. We’re the nation’s leader in CPR education training. We help people understand the importance of healthy lifestyle choices. We provide science-based treatment guidelines to healthcare professionals to help them provide quality care to their patients. We educate lawmakers, policymakers and the public as we advocate for changes to protect and improve the health of our communities.

Ampfuul's mission is to accelerate commercialization for our client's businesses in biotechnology and the life sciences by providing a suite of business development, marketing and sales services, including implementation of strategies.

Anavex™ Life Sciences Corp. is a clinical stage biopharmaceutical company engaged in the development of novel drug candidates to treat Alzheimer’s, CNS diseases and various types of cancer, which have significant unmet medical needs.

ANAVEX™ 2-73, the Company’s orally available drug candidate developed to treat Alzheimer’s through potential disease modification, has undergone an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg.  Results from pre-clinical studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties.

A highly encouraging synergistic effect has also been observed between ANAVEX 2-73 and donepezil (Aricept®).  The combined therapeutics, referred to as “ANAVEX™ PLUS,” produced up to 80% greater reversal of memory loss in Alzheimer’s disease models versus when the drugs were used individually.

ANAVEX PLUS is believed to be a compelling commercial opportunity.  The clinical trial risk is lower because donepezil (Aricept®) is already on the market, with global sales of $4-billion annually.  Donepezil (Aricept®) is now generic and a patent application has been filed for ANAVEX PLUS which, if granted, would provide protection until 2033.

Headquartered in New York, Anavex is an American publicly traded corporation quoted as AVXL.

Apollonia Health researches and develops innovative oral hygiene products that can safely and selectively eliminate cavity-causing bacteria.

Our company manufactures revolutionary oral healthcare products made only with naturally occurring ingredients. Because of this, our products can be used safely by children.

Starinse is the flagship oral health care product from Apollonia Health, Inc. Based in Ontario, Apollonia Health Inc. is an oral healthcare biotech company dedicated to researching, developing, and commercializing the most innovative oral hygiene products to improve the oral healthcare of children around the world.

Our name, Aptuit, is derived from the words aptitude and intuition, two natural attributes that define our unique approach to providing drug discovery, development and manufacturing support. The name communicates our aptitude for scientific knowledge as well as our intuitive understanding of the needs of the pharmaceutical and biotechnological community. We summon these attributes to clarify current challenges and anticipate those that are to come, always with the determination to find solutions.

Since Aptuit was founded in 2004, we have forged a robust expansion of our resources. We are living up to the promise of our name by the ongoing assembly of experienced and talented scientists, and we are supporting them every step of the way with the most advanced resources at state-of-the art facilities.

Our corporate tagline - Uncommon Expertise. Exceptional Results - reflects our success in harnessing unique and outstanding strengths in drug discovery and drug development to deliver the results that our clients demand.

The services we provide to help us achieve this vision are:

• Drug Design & Discovery
• Preclinical Biosciences
• API Development & Manufacture
• Solid State Chemistry
• Solid & Oral Dosage Form Development & Manufacture
• Integrated Drug Discovery & Drug Development
• Aptuit INDiGO®
• Physical & Analytical Chemistry

Argus Research is an independent research firm, and our business is producing, distributing and marketing high-quality investment and economic research.

Our recommendations - BUY, HOLD and SELL - reflect the judgment of an analyst about a company’s prospects as an investment in terms of value, expected growth and risks.

Argus Research does not bring companies public, advise companies on mergers and acquisitions, broker trades, make markets in stocks or manage money. Our independence allows us to make critical judgments about companies that we might not be so free to make were we competing for a firm’s underwriting business. Because we’re not a broker/dealer, we don’t have “inventory” of a stock that we have to move with a tainted recommendation.

In recent years, numerous academic studies have concluded that investors benefit from independent research. Here are some of the benefits:

Aligned Interests

The incentives to bias recommendations upward are stronger for brokerage analysts affiliated with Investment Banks, according to a Stanford Graduate School of Business study.

Transparency & Objectivity

The use of Independent Research through the Global Settlement has pulled optimism out of the market & cleared up rating confusion for retail investors, according to a Washington University/Case Western Reserve University study.

Performance

Independent Research Provider BUY ratings statistically and significantly outperform Investment Bank BUYS, according to a study published by the University of California-Davis, University of Michigan and University of California Los Angeles.

Single cell research has been identified as essential to the discovery of effective new drugs. Our team at ARL Designs has developed the Nano-Droplet Array Plate, an entirely new approach that satisfies this unmet need for isolating and studying individual cells over time.  Key to the proven success of this technology is our unique surface structure which causes nano-droplets to self-align and entrap individual cells at precise locations in large, high-density arrays.  Low fabrication costs will help drive this technology into the rapidly expanding market for 3D cell culture.